Sahin Mustafa, Jones Stephanie R, Sweeney John A, Berry-Kravis Elizabeth, Connors Barry W, Ewen Joshua B, Hartman Adam L, Levin April R, Potter William Z, Mamounas Laura A
Nat Rev Drug Discov. 2018 Dec 20. doi: 10.1038/d41573-018-00010-7.
Investment in drug development for neurodevelopmental disorders has suffered from recent failures in clinical trials that were based on promising preclinical findings. Here, we discuss development and validation of translational biomarkers of neurodevelopmental disorders that can enable more informative clinical experiments and translational success in these diseases.
针对神经发育障碍的药物研发投资,因近期基于有前景的临床前研究结果而开展的临床试验失败,受到了影响。在此,我们讨论神经发育障碍转化生物标志物的开发与验证,这些生物标志物能够使针对这些疾病的临床试验更具信息价值,并实现转化成功。